神州细胞(688520) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥328,779,509.01, representing a significant increase of 111.02% compared to the same period last year[4]. - The net profit attributable to shareholders of the listed company was a loss of ¥153,011,423.00, with a net profit excluding non-recurring gains and losses of a loss of ¥58,524,478.28[4]. - The company's net loss for Q1 2023 was ¥153,769,208.59, compared to a net loss of ¥118,198,000.00 in Q1 2022, representing a worsening of 30.1%[19]. - The net profit for Q1 2023 was -153,348,003.27 CNY, compared to -143,622,878.13 CNY in Q1 2022, indicating a year-over-year increase in losses of approximately 7.5%[21]. - The company reported a total comprehensive income of -153,348,003.27 CNY for Q1 2023, compared to -143,622,878.13 CNY in Q1 2022, reflecting a decline in overall financial performance[21]. Cash Flow - The net cash flow from operating activities was negative at ¥121,991,794.43[4]. - Cash flow from operating activities showed a net outflow of -121,991,794.43 CNY, worsening from -95,350,434.30 CNY in Q1 2022[23]. - The cash flow from investing activities resulted in a net outflow of -517,667,554.98 CNY, compared to -387,170,845.31 CNY in the previous year[24]. - The net cash flow from financing activities was -51,177,831.75 RMB, compared to 351,747,155.74 RMB in the previous year, indicating a substantial decline[32]. - The company reported a total cash outflow from operating activities of 11,025,610.45 RMB, compared to 10,068,905.02 RMB in the same quarter last year, an increase of approximately 9.5%[31]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,877,949,104.54, reflecting a 5.19% increase from the end of the previous year[5]. - Total liabilities rose to ¥3,266,245,838.84 in Q1 2023, up from ¥2,978,066,553.77 in Q1 2022, marking an increase of 9.7%[17]. - The total equity attributable to shareholders decreased to -¥382,420,147.87 as of March 31, 2023, from -¥236,650,939.28 at the end of 2022, indicating a decline of 61.6%[18]. - The company's total assets decreased to CNY 3,196,335,084.75 as of March 31, 2023, down from CNY 3,254,225,625.01 at the end of 2022, reflecting a decline of 1.77%[28]. - The total owner's equity decreased to CNY 2,571,237,580.62 as of March 31, 2023, down from CNY 2,582,956,396.48 at the end of 2022, a decline of 0.43%[28]. Research and Development - Research and development expenses totaled ¥270,002,471.74, which is an increase of 43.20% year-on-year[4]. - The ratio of R&D expenses to operating revenue was 82.12%, a decrease of 38.89 percentage points compared to the previous year[5]. - R&D expenses in Q1 2023 amounted to ¥248,165,462.86, compared to ¥184,747,212.74 in Q1 2022, indicating a rise of 34.3%[19]. - Research and development expenses decreased to CNY 1,405,310.16 in Q1 2023, down 49.5% from CNY 2,781,699.28 in Q1 2022[29]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,145[10]. - The company reported a basic and diluted earnings per share of -0.34 CNY for Q1 2023, slightly worse than -0.33 CNY in Q1 2022[22]. Government Support - The company received government subsidies amounting to ¥5,849,022.36 during the quarter[6]. Inventory and Borrowings - The company's inventory increased to ¥208,846,931.26 as of March 31, 2023, from ¥191,883,056.14 at the end of 2022, an increase of 8.9%[16]. - Short-term borrowings increased to ¥599,346,189.30 in Q1 2023, compared to ¥508,449,216.36 in Q1 2022, reflecting an increase of 17.9%[17].